Clinical trials: Perioperative Immunotherapy
Carcinoma, Hepatocellular, Immunotherapy
Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma
This study aims to retrospectively collect a cohort of participants with hepatocellular carcinoma who received immunotherapy-based neoadjuvant/translational treatment.
- Trial name
- NCT06571396
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qilu Hospital of Shandong University
Elective Surgical Procedures, Postoperative Pain
Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair
Open Abdominal Aortic Aneurysm (AAA) repair is a high-risk surgical procedure accompanied by intense endocrine and metabolic responses to surgical stress, with subsequent activation of the inflammatory cascade, cytokine and…
- Conditions
- Elective Surgical Procedures, Postoperative Pain, Anesthesia, Opioid Use
- Trial name
- NCT04894864
- Testing
- Opioid-Based Anesthesia-Analgesia Strategy, Opioid-free Anesthesia-Analgesia Strategy
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University of Crete
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
IMAGINE is a Phase II, randomized, two-arm, chemotherapy controlled modular trial in subjects with histologically confirmed, resectable gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (AEG).
- Trial name
- IMAGINE (NCT04062656)
- Testing
- Nivolumab, relatlimab, Oxaliplatin
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- University Hospital, Essen
Urothelial Bladder Carcinoma
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
The main objective of this trial is to evaluate the efficacy of the combo Sacituzumab govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as pathologic complete response (pCR) rates, in the…
- Trial name
- NCT06133517
- Testing
- Sacituzumab govitecan, Zimberelimab, Domvanalimab
- Where
- 6 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
Non-Small Cell Lung Cancer
An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
This is a single-center, open-label, single-arm phase II exploratory study evaluating a perioperative regimen of iparomlimab and tuvonralimab (QL1706; a bispecific PD-1/CTLA-4 antibody) combined with platinum-based chemotherapy…
- Trial name
- NCT07452003
- Testing
- QL1706 plus chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT05836584
- Testing
- Atezolizumab, Biospecimen Collection, Capecitabine
- Where
- 133 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Emotional Distress and Pathologic Response in Locally Advanced Gastric/GEJ Adenocarcinoma
This is a single-center, prospective observational cohort study designed to evaluate the association between pretreatment emotional distress and pathologic response to perioperative immunotherapy in patients with locally advanced…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Emotional Distress, Pathologic Response
- Trial name
- NCT07662070
- Testing
- Not applicable- observational study
- Volunteers
- 120 people
- Sponsor
- West China Second University Hospital
Gastric Cancer
An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC
1. Main objective: to evaluate the pathological complete response (pCR) of gastric cancer after local advanced COVID-19 infection by two kinds of immunotherapy combined with Anlotinib Hydrochloride Capsules and neoadjuvant…
- Trial name
- NCT05800080
- Testing
- Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Xijing Hospital
Lung Neoplasms, Neoadjuvant Therapy
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy.
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07894458
- Testing
- Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Billiary Track Cancer
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab…
- Trial name
- NCT06001658
- Testing
- Gemcitabine, Cisplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Squamous Cell Carcinoma (ESCC)
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
This study aims to examine the efficacy of the combination of neoadjuvant chemoradiotherapy and perioperative PD-1 inhibitor in patients with locally advanced esophageal squamous cell cancer and explore the predictive biomarkers…
- Trial name
- NCT06762158
- Testing
- Neoadjuvant Chemoradiotherapy, neoadjuvant immunotherapy, Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer
An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors
Gastrointestinal cancer like Gastric cancer and colorectal cancer are high-incidence tumors worldwide. Surgery is the only curable way. Perioperative treatment can improve the survival of patients.
- Trial name
- NCT04640103
- Testing
- No interventions
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shen Lin
NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The goal of this clinical trial is to learn if tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy works to treat for resectable stage II-IIIB driver gene-negative NSCLC.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
- Trial name
- NCT06977828
- Testing
- tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Resectable Stage II-IIIa NSCLC
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and…
- Trial name
- ECTOP-1030 (NCT07554846)
- Testing
- Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy
- Where
- China
- Volunteers
- 759 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Immunotherapy
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
This is a single-arm, multicenter, exploratory clinical study evaluating the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection (QL1706) and lenvatinib for perioperative treatment of resectable HCC…
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1
- Trial name
- NCT07131501
- Testing
- Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Mesothelioma, Peritoneal Mesothelioma
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
This study is for individuals who have peritoneal mesothelioma, a cancer of the lining of your abdominal wall and organs (the peritoneum).
- Trial name
- NCT05041062
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Stomach Neoplasms, Esophagogastric Junction Disorder
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage.
- Conditions
- Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy
- Trial name
- NeoRacing (NCT05161572)
- Testing
- Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma
The purpose of this study is to determine the safety and feasibility of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.
- Trial name
- NCT04658147
- Testing
- Nivolumab, Relatlimab
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
The goal of this study is to develop and refine an integrated minimally invasive care pathway for resectable lung cancer in the immunotherapy era, establishing a novel precision perioperative immunotherapy paradigm encompassing…
- Trial name
- NCT07119190
- Volunteers
- 350 people
- Sponsor
- Peking University People's Hospital
Esophagogastric Junction Adenocarcinoma
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study
The purpose of this study is to explore the effectiveness and safety of immunotherapy (Adebrelimab, a PD-L1 inhibitor) combined with standard chemotherapy (XELOX) in the perioperative treatment of resectable esophagogastric…
- Trial name
- AEGIS (NCT06482788)
- Testing
- Adebrelimab (anti-PD-L1) + XELOX
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Ruijin Hospital